The Efficacy and Safety of OnabotulinumtoxinA with Different Dosages for the Treatment of Overactive Bladder Syndrome: A Systematic Review and Meta-analysis

Lijun Mu; Enxu Xie; Xinwei Zhang; Juanhua Tian; Meiyu Wang; Dapeng Wu; Yuefeng Du

doi:doi:10.11648/j.ajls.20210905.16

| Peer-Reviewed

The Efficacy and Safety of OnabotulinumtoxinA with Different Dosages for the Treatment of Overactive Bladder Syndrome: A Systematic Review and Meta-analysis

Lijun Mu, Enxu Xie, Xinwei Zhang, Juanhua Tian, Meiyu Wang, Dapeng Wu, Yuefeng Du

Published in American Journal of Life Sciences (Volume 9, Issue 5)

Received: 6 October 2021 Accepted: 30 October 2021 Published: 5 November 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

OnabotulinumtoxinA therapy has become widely used in overactive bladder syndrome (OAB), and many relevant articles have been published, however, there is no consensus regarding the clinical effect of onabotulinumtoxinA with the different dosages. Therefore, we conducted this meta-analysis to assess the efficacy and safety of 100 U, 200 U and 300 U onabotulinumtoxinA for the treatment of (OAB). In this project, We performed a comprehensive literature search, which was performed using EMBASE, PubMed, Cochrane database, and Google Scholar for randomized controlled trials (from inception to February 2017). As a result, fourteen studies with 1999 participants were selected. For the efficacy, 200 U of OnabotulinumtoxinA was significantly superior to 100 U, especially in the maximum cystometric capacity (MCC) and maximum detrusor pressure (MDP). Also, its subjective cure rate showed the same tendency. There were no statistical differences between 200 U and 300 U in MCC, MDP and subjective cure rate. For the adverse events, there were no statistical differences among 100 U, 200 U and 300 U OnabotulinumtoxinA in urinary tract infection (UTI) and urinary retention. Therefore, in our study. Compared to 100 U OnabotulinumtoxinA, 200 U OnabotulinumtoxinA has better efficacy while maintaining safety. Although 200 U OnabotulinumtoxinA is comparable to 300 U OnabotulinumtoxinA in terms of safety and efficacy, 200 U OnabotulinumtoxinA is a cost-effective intervention and may appear to be the optimal dosage for OAB populations.

Published in	American Journal of Life Sciences (Volume 9, Issue 5)
DOI	10.11648/j.ajls.20210905.16
Page(s)	141-148
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

OnabotulinumtoxinA, Overactive Bladder, Dosages

References

[1]	Apostolidis A, Thompson C, Yan X, Mourad S: An exploratory, placebo-controlled, dose-response study of the efficacy and safety of onabotulinumtoxinA in spinal cord injury patients with urinary incontinence due to neurogenic detrusor overactivity. World journal of urology 2013, 31 (6): 1469-1474.
[2]	Jundt K, Schreyer K, Friese K, Peschers U: Anticholinergic therapy: do the patients take the pills prescribed? Arch Gynecol Obstet 2011, 284 (3): 663-666.
[3]	Cheng T, Shuang WB, Jia DD, Zhang M, Tong XN, Yang WD, Jia XM, Li S: Efficacy and Safety of OnabotulinumtoxinA in Patients with Neurogenic Detrusor Overactivity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One 2016, 11 (7): e0159307.
[4]	Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, Plante P, Perrouin-Verbe B, Kumar C, Fraczek S et al: Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005, 174 (1): 196-200.
[5]	Abdelwahab O, Sherif H, Soliman T, Elbarky I, Eshazly A: Efficacy of botulinum toxin type A 100 Units versus 200 units for treatment of refractory idiopathic overactive bladder. Int Braz J Urol 2015, 41 (6): 1132-1140.
[6]	Brubaker L, Gousse A, Sand P, Thompson C, Patel V, Zhou J, Jenkins B, Sievert KD: Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. Int Urogynecol J 2012, 23 (8): 1017-1025.
[7]	Fowler CJ, Auerbach S, Ginsberg D, Hale D, Radziszewski P, Rechberger T, Patel VD, Zhou J, Thompson C, Kowalski JW: OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial. Eur Urol 2012, 62 (1): 148-157.
[8]	Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P: Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn 2013, 32 (3): 242-249.
[9]	Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P: Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 2011, 30 (4): 556-562.
[10]	Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C: OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity. Neurourol Urodyn 2013, 32 (8): 1109-1115.
[11]	Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C: Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol 2012, 187 (6): 2131-2139.
[12]	Schurch B, Denys P, Kozma CM, Reese PR, Slaton T, Barron RL: Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence. Eur Urol 2007, 52 (3): 850-858.
[13]	Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, Daniell G, Zhou J, Haag-Molkenteller C: Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol 2010, 184 (6): 2416-2422.
[14]	Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C: Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol 2011, 60 (4): 742-750.
[15]	Altaweel W, Mokhtar A, Rabah DM: Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder. Urol Ann 2011, 3 (2): 66-70.
[16]	Kuo HC: Will suburothelial injection of small dose of botulinum A toxin have similar therapeutic effects and less adverse events for refractory detrusor overactivity? Urology 2006, 68 (5): 993-997; discussion 997-998.
[17]	Barbagli G, Heidenreich A, Zugor V, Karapanos L, Lazzeri M: Urothelial or oral mucosa cells for tissue-engineered urethroplasty: A critical revision of the clinical outcome. Asian J Urol 2020, 7 (1): 18-23.
[18]	Rapp DE, Lucioni A, Bales GT: Botulinum toxin injection: a review of injection principles and protocols. Int Braz J Urol 2007, 33 (2): 132-141.
[19]	Bagi P, Biering-Sorensen F: Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scandinavian journal of urology and nephrology 2004, 38 (6): 495-498.
[20]	Leippold T, Reitz A, Schurch B: Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003, 44 (2): 165-174.
[21]	Albanese A: Terminology for preparations of botulinum neurotoxins: what a difference a name makes. Jama 2011, 305 (1): 89-90.
[22]	Sun Y, Luo D, Tang C, Yang L, Shen H: The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis. International urology and nephrology 2015, 47 (11): 1779-1788.
[23]	Cui Y, Zhou X, Zong H, Yan H, Zhang Y: The efficacy and safety of onabotulinumtoxinA in treating idiopathic OAB: A systematic review and meta-analysis. Neurourol Urodyn 2015, 34 (5): 413-419.
[24]	Zhou X, Yan HL, Cui YS, Zong HT, Zhang Y: Efficacy and safety of onabotulinumtoxinA in treating neurogenic detrusor overactivity: a systematic review and meta-analysis. Chinese medical journal 2015, 128 (7): 963-968.
[25]	Persu C: 300 IU vs. 200 IU of OnabotulinumtoxinA for detrusor overactivity. Central European journal of urology 2014, 67 (1): 41-42.
[26]	Seth JH, Dowson C, Khan MS, Panicker JN, Fowler CJ, Dasgupta P, Sahai A: Botulinum toxin-A for the treatment of overactive bladder: UK contributions. Journal of clinical urology 2013, 6 (2): 77-83.
[27]	Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, Sievert KD, Brin MF, Jenkins B, Thompson C et al: OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity regardless of concomitant anticholinergic use or neurologic etiology. Adv Ther 2013, 30 (9): 819-833.

Cite This Article

Plain Text BibTeX RIS

APA Style

Lijun Mu, Enxu Xie, Xinwei Zhang, Juanhua Tian, Meiyu Wang, et al. (2021). The Efficacy and Safety of OnabotulinumtoxinA with Different Dosages for the Treatment of Overactive Bladder Syndrome: A Systematic Review and Meta-analysis. American Journal of Life Sciences, 9(5), 141-148. https://doi.org/10.11648/j.ajls.20210905.16

Copy | Download

ACS Style

Lijun Mu; Enxu Xie; Xinwei Zhang; Juanhua Tian; Meiyu Wang, et al. The Efficacy and Safety of OnabotulinumtoxinA with Different Dosages for the Treatment of Overactive Bladder Syndrome: A Systematic Review and Meta-analysis. Am. J. Life Sci. 2021, 9(5), 141-148. doi: 10.11648/j.ajls.20210905.16

Copy | Download

AMA Style

Lijun Mu, Enxu Xie, Xinwei Zhang, Juanhua Tian, Meiyu Wang, et al. The Efficacy and Safety of OnabotulinumtoxinA with Different Dosages for the Treatment of Overactive Bladder Syndrome: A Systematic Review and Meta-analysis. Am J Life Sci. 2021;9(5):141-148. doi: 10.11648/j.ajls.20210905.16

Copy | Download

@article{10.11648/j.ajls.20210905.16,
  author = {Lijun Mu and Enxu Xie and Xinwei Zhang and Juanhua Tian and Meiyu Wang and Dapeng Wu and Yuefeng Du},
  title = {The Efficacy and Safety of OnabotulinumtoxinA with Different Dosages for the Treatment of Overactive Bladder Syndrome: A Systematic Review and Meta-analysis},
  journal = {American Journal of Life Sciences},
  volume = {9},
  number = {5},
  pages = {141-148},
  doi = {10.11648/j.ajls.20210905.16},
  url = {https://doi.org/10.11648/j.ajls.20210905.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajls.20210905.16},
  abstract = {OnabotulinumtoxinA therapy has become widely used in overactive bladder syndrome (OAB), and many relevant articles have been published, however, there is no consensus regarding the clinical effect of onabotulinumtoxinA with the different dosages. Therefore, we conducted this meta-analysis to assess the efficacy and safety of 100 U, 200 U and 300 U onabotulinumtoxinA for the treatment of (OAB). In this project, We performed a comprehensive literature search, which was performed using EMBASE, PubMed, Cochrane database, and Google Scholar for randomized controlled trials (from inception to February 2017). As a result, fourteen studies with 1999 participants were selected. For the efficacy, 200 U of OnabotulinumtoxinA was significantly superior to 100 U, especially in the maximum cystometric capacity (MCC) and maximum detrusor pressure (MDP). Also, its subjective cure rate showed the same tendency. There were no statistical differences between 200 U and 300 U in MCC, MDP and subjective cure rate. For the adverse events, there were no statistical differences among 100 U, 200 U and 300 U OnabotulinumtoxinA in urinary tract infection (UTI) and urinary retention. Therefore, in our study. Compared to 100 U OnabotulinumtoxinA, 200 U OnabotulinumtoxinA has better efficacy while maintaining safety. Although 200 U OnabotulinumtoxinA is comparable to 300 U OnabotulinumtoxinA in terms of safety and efficacy, 200 U OnabotulinumtoxinA is a cost-effective intervention and may appear to be the optimal dosage for OAB populations.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - The Efficacy and Safety of OnabotulinumtoxinA with Different Dosages for the Treatment of Overactive Bladder Syndrome: A Systematic Review and Meta-analysis
AU  - Lijun Mu
AU  - Enxu Xie
AU  - Xinwei Zhang
AU  - Juanhua Tian
AU  - Meiyu Wang
AU  - Dapeng Wu
AU  - Yuefeng Du
Y1  - 2021/11/05
PY  - 2021
N1  - https://doi.org/10.11648/j.ajls.20210905.16
DO  - 10.11648/j.ajls.20210905.16
T2  - American Journal of Life Sciences
JF  - American Journal of Life Sciences
JO  - American Journal of Life Sciences
SP  - 141
EP  - 148
PB  - Science Publishing Group
SN  - 2328-5737
UR  - https://doi.org/10.11648/j.ajls.20210905.16
AB  - OnabotulinumtoxinA therapy has become widely used in overactive bladder syndrome (OAB), and many relevant articles have been published, however, there is no consensus regarding the clinical effect of onabotulinumtoxinA with the different dosages. Therefore, we conducted this meta-analysis to assess the efficacy and safety of 100 U, 200 U and 300 U onabotulinumtoxinA for the treatment of (OAB). In this project, We performed a comprehensive literature search, which was performed using EMBASE, PubMed, Cochrane database, and Google Scholar for randomized controlled trials (from inception to February 2017). As a result, fourteen studies with 1999 participants were selected. For the efficacy, 200 U of OnabotulinumtoxinA was significantly superior to 100 U, especially in the maximum cystometric capacity (MCC) and maximum detrusor pressure (MDP). Also, its subjective cure rate showed the same tendency. There were no statistical differences between 200 U and 300 U in MCC, MDP and subjective cure rate. For the adverse events, there were no statistical differences among 100 U, 200 U and 300 U OnabotulinumtoxinA in urinary tract infection (UTI) and urinary retention. Therefore, in our study. Compared to 100 U OnabotulinumtoxinA, 200 U OnabotulinumtoxinA has better efficacy while maintaining safety. Although 200 U OnabotulinumtoxinA is comparable to 300 U OnabotulinumtoxinA in terms of safety and efficacy, 200 U OnabotulinumtoxinA is a cost-effective intervention and may appear to be the optimal dosage for OAB populations.
VL  - 9
IS  - 5
ER  -

Copy | Download

Author Information

Lijun Mu

Department of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Enxu Xie

Department of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Xinwei Zhang

Department of Urology, Xi'an Children’s Hospital, Xi'an, China
Juanhua Tian

Department of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Meiyu Wang

Department of Imaging, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
Dapeng Wu

Department of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China
Yuefeng Du

Department of Urology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Lijun Mu, Enxu Xie, Xinwei Zhang, Juanhua Tian, Meiyu Wang, et al. (2021). The Efficacy and Safety of OnabotulinumtoxinA with Different Dosages for the Treatment of Overactive Bladder Syndrome: A Systematic Review and Meta-analysis. American Journal of Life Sciences, 9(5), 141-148. https://doi.org/10.11648/j.ajls.20210905.16

Copy | Download

ACS Style

Lijun Mu; Enxu Xie; Xinwei Zhang; Juanhua Tian; Meiyu Wang, et al. The Efficacy and Safety of OnabotulinumtoxinA with Different Dosages for the Treatment of Overactive Bladder Syndrome: A Systematic Review and Meta-analysis. Am. J. Life Sci. 2021, 9(5), 141-148. doi: 10.11648/j.ajls.20210905.16

Copy | Download

AMA Style

Lijun Mu, Enxu Xie, Xinwei Zhang, Juanhua Tian, Meiyu Wang, et al. The Efficacy and Safety of OnabotulinumtoxinA with Different Dosages for the Treatment of Overactive Bladder Syndrome: A Systematic Review and Meta-analysis. Am J Life Sci. 2021;9(5):141-148. doi: 10.11648/j.ajls.20210905.16

Copy | Download

@article{10.11648/j.ajls.20210905.16,
  author = {Lijun Mu and Enxu Xie and Xinwei Zhang and Juanhua Tian and Meiyu Wang and Dapeng Wu and Yuefeng Du},
  title = {The Efficacy and Safety of OnabotulinumtoxinA with Different Dosages for the Treatment of Overactive Bladder Syndrome: A Systematic Review and Meta-analysis},
  journal = {American Journal of Life Sciences},
  volume = {9},
  number = {5},
  pages = {141-148},
  doi = {10.11648/j.ajls.20210905.16},
  url = {https://doi.org/10.11648/j.ajls.20210905.16},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajls.20210905.16},
  abstract = {OnabotulinumtoxinA therapy has become widely used in overactive bladder syndrome (OAB), and many relevant articles have been published, however, there is no consensus regarding the clinical effect of onabotulinumtoxinA with the different dosages. Therefore, we conducted this meta-analysis to assess the efficacy and safety of 100 U, 200 U and 300 U onabotulinumtoxinA for the treatment of (OAB). In this project, We performed a comprehensive literature search, which was performed using EMBASE, PubMed, Cochrane database, and Google Scholar for randomized controlled trials (from inception to February 2017). As a result, fourteen studies with 1999 participants were selected. For the efficacy, 200 U of OnabotulinumtoxinA was significantly superior to 100 U, especially in the maximum cystometric capacity (MCC) and maximum detrusor pressure (MDP). Also, its subjective cure rate showed the same tendency. There were no statistical differences between 200 U and 300 U in MCC, MDP and subjective cure rate. For the adverse events, there were no statistical differences among 100 U, 200 U and 300 U OnabotulinumtoxinA in urinary tract infection (UTI) and urinary retention. Therefore, in our study. Compared to 100 U OnabotulinumtoxinA, 200 U OnabotulinumtoxinA has better efficacy while maintaining safety. Although 200 U OnabotulinumtoxinA is comparable to 300 U OnabotulinumtoxinA in terms of safety and efficacy, 200 U OnabotulinumtoxinA is a cost-effective intervention and may appear to be the optimal dosage for OAB populations.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - The Efficacy and Safety of OnabotulinumtoxinA with Different Dosages for the Treatment of Overactive Bladder Syndrome: A Systematic Review and Meta-analysis
AU  - Lijun Mu
AU  - Enxu Xie
AU  - Xinwei Zhang
AU  - Juanhua Tian
AU  - Meiyu Wang
AU  - Dapeng Wu
AU  - Yuefeng Du
Y1  - 2021/11/05
PY  - 2021
N1  - https://doi.org/10.11648/j.ajls.20210905.16
DO  - 10.11648/j.ajls.20210905.16
T2  - American Journal of Life Sciences
JF  - American Journal of Life Sciences
JO  - American Journal of Life Sciences
SP  - 141
EP  - 148
PB  - Science Publishing Group
SN  - 2328-5737
UR  - https://doi.org/10.11648/j.ajls.20210905.16
AB  - OnabotulinumtoxinA therapy has become widely used in overactive bladder syndrome (OAB), and many relevant articles have been published, however, there is no consensus regarding the clinical effect of onabotulinumtoxinA with the different dosages. Therefore, we conducted this meta-analysis to assess the efficacy and safety of 100 U, 200 U and 300 U onabotulinumtoxinA for the treatment of (OAB). In this project, We performed a comprehensive literature search, which was performed using EMBASE, PubMed, Cochrane database, and Google Scholar for randomized controlled trials (from inception to February 2017). As a result, fourteen studies with 1999 participants were selected. For the efficacy, 200 U of OnabotulinumtoxinA was significantly superior to 100 U, especially in the maximum cystometric capacity (MCC) and maximum detrusor pressure (MDP). Also, its subjective cure rate showed the same tendency. There were no statistical differences between 200 U and 300 U in MCC, MDP and subjective cure rate. For the adverse events, there were no statistical differences among 100 U, 200 U and 300 U OnabotulinumtoxinA in urinary tract infection (UTI) and urinary retention. Therefore, in our study. Compared to 100 U OnabotulinumtoxinA, 200 U OnabotulinumtoxinA has better efficacy while maintaining safety. Although 200 U OnabotulinumtoxinA is comparable to 300 U OnabotulinumtoxinA in terms of safety and efficacy, 200 U OnabotulinumtoxinA is a cost-effective intervention and may appear to be the optimal dosage for OAB populations.
VL  - 9
IS  - 5
ER  -

Copy | Download